SYNAGIS Market Size, Forecast, and Market Insight - 2032

“SYNAGIS Market Size, Forecast, and Market Insight - 2032” report provides comprehensive insights about SYNAGIS for Respiratory syncytial virus (RSV) in the seven major markets. A detailed picture of the SYNAGIS for RSV in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the SYNAGIS for RSV. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the SYNAGIS market forecast analysis for RSV in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in RSV.

Drug Summary

SYNAGIS (Palivizumab) is a humanized monoclonal antibody (IgG1к) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of RSV. Palivizumab is a composite of human (95%) and murine (5%) antibody sequences. The human heavy chain sequence was derived from the constant domains of human IgG1 and the variable framework regions of the VH genes Cor and Cess. The human light chain sequence was derived from the constant domain of Cк and the variable framework regions of the VL gene K104 with Jк-4. The murine sequences were derived from a murine monoclonal antibody, Mab 1129, in a process that involved grafting the murine complementarity determining regions into the human antibody frameworks. Palivizumab is composed of two heavy and light chains and has a molecular weight of approximately 148,000 Da. SYNAGIS is supplied as a sterile, preservative-free liquid solution at 100 mg per mL to be administered by intramuscular injection. Thimerosal or other mercury-containing salts are not used in the production of SYNAGIS. The solution has a pH of 6.0 and should appear clear or slightly opalescent. Each 100 mg single-dose vial of SYNAGIS liquid solution contains 100 mg of palivizumab and also contains chloride (0.5 mg), glycine (0.1 mg), and histidine (3.9 mg) in a volume of 1 mL. Each 50 mg single-dose vial of SYNAGIS liquid solution contains 50 mg of palivizumab and also contains chloride (0.2 mg), glycine (0.06 mg), and histidine (1.9 mg), in a volume of 0.5 ml.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the SYNAGIS description, mechanism of action, dosage and administration, research and development activities in Respiratory syncytial virus (RSV).
• Elaborated details on SYNAGIS regulatory milestones and other development activities have been provided in this report.
• The report also highlights the SYNAGIS research and development activities in RSV across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around SYNAGIS.
• The report contains forecasted sales of SYNAGIS for RSV till 2032.
• Comprehensive coverage of the late-stage emerging therapies for RSV.
• The report also features the SWOT analysis with analyst views for SYNAGIS in RSV.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the publisher’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

SYNAGIS Analytical Perspective

In-depth SYNAGIS Market Assessment

This report provides a detailed market assessment of SYNAGIS for Respiratory syncytial virus (RSV) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

SYNAGIS Clinical Assessment

The report provides the clinical trials information of SYNAGIS for RSV covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Respiratory syncytial virus (RSV) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence SYNAGIS dominance.
• Other emerging products for RSV are expected to give tough market competition to SYNAGIS and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of SYNAGIS in RSV.
• Our in-depth analysis of the forecasted sales data of SYNAGIS from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the SYNAGIS in RSV.

Key Questions Answered

• What is the product type, route of administration and mechanism of action of SYNAGIS?
• What is the clinical trial status of the study related to SYNAGIS in Respiratory syncytial virus (RSV) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the SYNAGIS development?
• What are the key designations that have been granted to SYNAGIS for RSV?
• What is the forecasted market scenario of SYNAGIS for RSV?
• What are the forecasted sales of SYNAGIS in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to SYNAGIS for RSV?
• Which are the late-stage emerging therapies under development for the treatment of RSV?

This product will be delivered within 2 business days.